Comparison · NCT01492101-sae
NKTR-102 vs Physician's Treatment of Choice: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. NKTR-102 vs Physician's Treatment of Choice: serious adverse events. Trial comparisons, record NCT01492101-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01492101-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.301 | 0.26 | 0.346 | wilson | |
| Risk in group 2 | 0.318 | 0.274 | 0.365 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0166 | -0.0792 | 0.0461 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.948 | 0.774 | 1.16 | log | |
| Odds ratio, group 1 over group 2 | 0.925 | 0.69 | 1.24 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on NKTR-102 than on Physician's Treatment of Choice | 60.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | NKTR-102 | NKTR-102: 145 mg/m2 NKTR-102 will be delivered q21day as a 90 minute intravenous (IV) infusion on day 1 of each treatment cycle. | 128 | 425 | EG000 |
| Group 2 | Physician's Treatment of Choice | Treatment of Physician's Choice (TPC): One of the following Treatment of Physician Choice will be administered per standard of care:~eribulin ixabepilone vinorelbine gemcitabine paclitaxel docetaxel or nab-paclitaxel | 129 | 406 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Up to 38 months.
Source ClinicalTrials.gov
Trial
- Title
- The BEACON Study (Breast Cancer Outcomes With NKTR-102)
- NCT number
- NCT01492101
- Phases
- PHASE3
- Conditions
- Locally Recurrent Breast Cancer, Metastatic Breast Cancer
- Interventions
- NKTR-102, Treatment of Physician's Choice (TPC)
- Lead sponsor
- Nektar Therapeutics
- Results first posted
- 2021-06-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01492101?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01492101-sae